hexapeptide-11
FVAPFP, Phe-Val-Ala-Pro-Phe-Pro, yeast-derived hexapeptide
Hexapeptide-11 is a six-residue peptide, Phe-Val-Ala-Pro-Phe-Pro, originally isolated from Saccharomyces cerevisiae extracts; the same sequence also occurs within casein and has been recovered from fermented casein hydrolysates. It has better laboratory characterisation than most cosmetic peptides (activation of the proteasome and autophagy and protection of fibroblasts from oxidative senescence), but the key paper carries commercial co-authorship and also reports an inconvenient finding the marketing omits.
Mechanism
The best-characterised action of hexapeptide-11 is on the proteostasis network, the cellular machinery for degrading damaged proteins. Sklirou and colleagues showed in human diploid fibroblasts that the peptide increases nuclear accumulation of Nrf2, the master transcription factor for the antioxidant response, raises expression of proteasomal protein subunits and proteasome peptidase activities, and activates proteasome, autophagy, chaperone and antioxidant-response genes in a dose- and time-dependent way. Declining proteasome and autophagic capacity is a well-established cellular hallmark of ageing, so a compound raising both is mechanistically interesting in a way most cosmetic peptides are not. Consistent with this, the peptide protected fibroblasts against oxidative-stress-mediated premature senescence without measurable toxicity in lung or skin fibroblasts. The same paper also found that hexapeptide-11 induced the activity of extracellular matrix metalloproteinases and suppressed cell migration, results that complicate any simple 'builds and protects matrix' story and that cosmetic accounts of this ingredient routinely omit.
A separate line of work by Gruber and colleagues examined the same sequence in intrinsically aged fibroblasts, extrinsically aged fibroblasts and dermal papilla cells, reporting dose-dependent, reversible downregulation of ATM and p53, proteins central to the DNA damage response that drives senescence entry. The physicochemical picture is less flattering: the peptide is moderately hydrophobic because of its two phenylalanines but carries no lipid anchor, and no penetration study in human skin has been published, so how much reaches viable dermis from a cosmetic formulation is unknown.
What the research shows
Sklirou and colleagues reported that hexapeptide-11 showed no significant toxicity in normal human diploid lung or skin fibroblasts, promoted dose- and time-dependent activation of proteasome, autophagy, chaperone and antioxidant-response genes, increased nuclear Nrf2, raised proteasomal subunit expression and peptidase activities, and conferred significant protection against oxidative-stress-mediated premature senescence. They also reported improved skin elasticity in in vivo human skin deformation assays (the only human data in the published record for this peptide, reported without trial methodology) and, notably, that the peptide induced extracellular matrix metalloproteinase activity and suppressed cell migration.
Gruber, Ludwig and Holtz tested concentrations between 0.1 and 1.0 per cent in intrinsically aged fibroblasts, extrinsically aged fibroblasts and aged dermal papilla cells, finding dose-dependent and reversible downregulation of ATM and p53. Wu and colleagues, screening five peptides in hydrogen-peroxide-stressed fibroblasts, identified 400 micrograms per millilitre as hexapeptide-11's optimal concentration for hydroxyproline content, not, as is sometimes reported, for elastin, and not as the winner of a between-peptide comparison; the elastin increase in that paper came from a four-peptide mixture. A 2025 dairy-science paper identified the closely related sequence Phe-Val-Ala-Pro-Phe-Pro-Glu in fermented casein hydrolysate with anti-inflammatory and antioxidant activity in microglial culture, unrelated to skincare but confirming the motif is a genuine food-derived bioactive. What remains absent is any controlled clinical trial with wrinkle, elasticity or barrier endpoints, and any published human penetration data.
Evidence assessment
Preclinical only
The draft this record corrects assigned 'limited' and described the research as academic and independent of the supplier. Both need correcting. The Sklirou paper's co-author list includes a natural-products cosmetics company and the ingredient's commercial supplier alongside the University of Athens groups, so it is not supplier-independent. Its human component is not a trial: it is an in vivo skin deformation assay reported as one sub-experiment within an otherwise in vitro paper, with no stated sample size, control arm, randomisation or blinding. Every study entry that survived this audit is preclinical or mechanistic in tier, and by the library's own rule that fixes the record at 'preclinical'. The cell-level work remains genuinely better than most of this category, and the Gruber and Wu papers are separate groups, but decent cell work is not clinical evidence.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts Preclinical only
No significant cytotoxicity; dose- and time-dependent activation of proteasome, autophagy, chaperone and antioxidant genes; increased nuclear Nrf2, proteasomal subunit expression and peptidase activity; significant protection against oxidative-stress-mediated premature senescence; improved skin elasticity in human deformation assays. The peptide also induced extracellular MMP activity and suppressed cell migration.
Modulation of cellular senescence in fibroblasts and dermal papillae cells in vitro Preclinical only
Hexapeptide-11 at 0.1 to 1.0 per cent produced dose-dependent, reversible downregulation of ATM and p53, proteins central to senescence entry.
Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts Preclinical only
400 micrograms per millilitre was hexapeptide-11's optimal concentration for hydroxyproline content. Increased elastin was reported for a four-peptide mixture, not for hexapeptide-11 alone.
Identification of bioaccessible and neuroprotective peptides from fermented casein hydrolysate Preclinical only
Identified Phe-Val-Ala-Pro-Phe-Pro-Glu in fermented casein hydrolysate with anti-inflammatory and antioxidant activity in lipopolysaccharide-stimulated microglia.
Safety
No safety signal has been reported. Sklirou and colleagues specifically assessed cytotoxicity in two normal human fibroblast lines and found none at active concentrations, which is more direct safety characterisation than most cosmetic peptides have. The sequence occurs naturally in casein and in yeast extracts, so dietary exposure to the motif is routine. The reported induction of extracellular matrix metalloproteinase activity is worth noting for completeness. MMP induction is a matrix-degrading signal, and it has not been characterised in intact human skin at cosmetic exposures. There are no sensitisation data in the public literature, no reproductive or developmental data, and no human pregnancy or lactation data. This is a topical cosmetic ingredient and has not been evaluated for injection or ingestion as a supplement.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained Regulation (EC) No 1223/2009); not listed in any prohibited or restricted annex. Requires a Cosmetic Product Safety Report and responsible person. No MHRA medicines authorisation. |
| United States | Not an FDA-approved drug and not covered by an OTC drug monograph; marketed as a cosmetic ingredient under the FD&C Act as amended by the Modernization of Cosmetics Regulation Act 2022. Claims referencing cellular senescence or the DNA damage response could be read as drug claims depending on wording. |
| WADA (sport) | Not named on the WADA Prohibited List. Topical cosmetic use raises no anti-doping issue. |
Questions
It was originally isolated from Saccharomyces cerevisiae extracts and later made by solid-phase synthesis. The same six-residue sequence, Phe-Val-Ala-Pro-Phe-Pro, has since been recovered from fermented casein hydrolysates, so the motif occurs naturally in both yeast and dairy protein. Cosmetic material is synthetic.
Not as independent as often claimed. The main 2015 paper came out of University of Athens laboratories but carries co-authors from a natural-products cosmetics company and from the ingredient's commercial supplier. Two other groups have tested the peptide separately, which does add weight, but the flagship paper is not free of commercial involvement.
It means the peptide increased the cell's capacity to clear damaged proteins, raising nuclear Nrf2, proteasome subunit expression and peptidase activity, and engaging autophagy. Declining capacity in these systems is a recognised feature of cellular ageing, so raising it is a coherent target rather than a marketing abstraction. The same paper also found the peptide induced matrix metalloproteinase activity, which is less flattering and rarely mentioned.
No. The only human data are skin deformation measurements reported as a sub-experiment inside the 2015 laboratory paper, with no stated sample size, control group or randomisation. No independent clinical replication has been published.